HighQC™ Human IPSC From LCL-Parkinson’s Disease

Description

HighQC™ Human IPSC From LCL-Parkinson’s Disease is a disease-specific human induced pluripotent stem cell (iPSC) line. It maintains pluripotency for Parkinson’s disease neural mechanism exploration. It was generated by reprogramming a lymphoblastoid cell line (LCL), originally derived from the peripheral blood mononuclear cells (PBMCs) of a donor diagnosed with Parkinson’s Disease. The reprogramming was performed using non-integrating episomal plasmid method. The resulting iPSCs (induced pluripotent stem cells) exhibit adherent growth with well-defined borders and a high nucleus-to-cytoplasm ratio. These cells retain the fundamental capacity for trilineage differentiation into cell types of the ectoderm, mesoderm, and endoderm germ layers. Core pluripotency marker SSEA-4 is expressed. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.